Subsidiary secures 7.3B KRW AI diagnostic contract
씨엑스아이
900120
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=811
Risk-adjusted indicator based on 811 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Contract Amount: 7,301,005,300 KRW (33,790,000 CNY)
- • Percentage of Recent Revenue: 13.56%
- • Subsidiary's Asset Ratio: 92.02% of consolidated assets
- • Contract Period: July 27, 2026 - July 26, 2027 (1 year)
AI Analysis Summary
CXI Healthcare Technology Group's subsidiary, Fujian Yongsheng Vitality Biotechnology Co., Ltd., secured an AI diagnostic system technical support service contract worth 7.3 billion KRW (33.79 million CNY) with Huamei Haolian Medical Technology (Beijing) Co., Ltd. This contract represents 13.56% of the subsidiary's recent annual revenue of 53.84 billion KRW and is valid for one year from July 27, 2026, to July 26, 2027. The contract value is based on an average of 220,000 annual users at 155 CNY per user/session. The significant contract value relative to revenue and the subsidiary's large asset contribution (92.02%) indicate a positive financial impact.
How This Event Is Evaluated
Strategic Contract Evaluation
Contract events are evaluated by measuring business scale, revenue relevance, counterparty quality, and execution visibility.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Contract size relative to company revenue
- Expected revenue impact
- Counterparty quality
- Contract duration and execution period
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.